Post by
canadafan on Mar 05, 2024 6:33pm
Need to clarify & very clear
It was stated , that you are tired of Matt running his own or Onc going it alone.
Plain language, ONC has never eluded, suggested or indicated they would be doing a phase 3 trial alone.
Since Day one ( articles of incorporation & founding business plan).
oncolytics biotech is a start up pharma company. Only goal to to prove Pelareorep is able yo get to market.
That will require a license deal, partnership and/ or sale of the company.
It has been discussed many times at KOL & general updates.
" The cost of phase 3 trial is prohibitive for ONC to proceed without big pharma assistance"
Andrew G, now gone, mentioned the estimated cost to move through a phase 3, get approval & market a product is " about" a $300million comitment.
That number would be on top of aquiring Onc.
So why so long. Roche or others need a solid strength of their decision to proceed.
From ONc perspective?
imho they have never been in such a strong clinical position.
MBc cancer phase 3 & MBc phase 3..both with FDA fast track approval.
Add in a few other side trials, all looking solid.
Problem?
They need both operating $$ and a partner to get to next level.
Reminds me of Nicola Tesla. Way back he had a contract with Westinghouse.
He was to receive infinte royalties based on every KW rating of electrical devices using his patented phase 3 A/c power.
in todsys $, he would have been wealthier than even the richest billionaires of today.
What happened?
There was a recession, Westinghouse & others were hurting. The banks did not welcome the royalty load, on top of failing bottom lines.
Nickola Tesla had the best patitent, the best proven technology of the time, yet the buisiness world was not in favour if his success.
He was bought out, for YES a very large sum. Howevr a fraction of the long term potentioal.
Why the comparison?
IMHO Pelareorep is within a notch of getting to market.
pelareorep, might be the very best option. Proven safe,
iV delivery, does not require special handling. It finds the cancer.
Does it work? The recent pancreatic cancer trial with Roche generated results that in if them selves were block buster.
Creating a very fast progress to FDA approval to proceed to phase 3 trial.
Regretably the PanCan cancellation out the breaks on that progress.
So they are in a $$ squeeze. Terrible timing.
Moving forward, something $$ needs to be done.
everybody knows that.
Investors, analysts, Onc management, potential pharma parteners,
What ever $$ deal comes forward, let's hope for the best.
again. Complete sale, partership, or a complete reorganization of the business model.
id like to bookend as I started.
Onc is not & can not do a phase 3 trial alone.
One caveat to that statement; in its existing business model.
stay tuned.
Comment by
lonc17 on Mar 05, 2024 7:50pm
It's been a year and a half since the "stellar" prelinary P2 panc results were announced. MC has failed to close a deal with BP (partnership or buyout) despite having more than enough time. He has failed. What's more will he bring to the table in the next few weeks or months? The CC on Thursday will be very revealing. More BS or some real substance from ONC?
Comment by
lonc17 on Mar 05, 2024 8:32pm
Preliminary... my eyes get worse every day, it seems. Also, the strongest evidence to back up a claim of very poor prospects for ONC is.... .... MC announced in December that his company was over valued. I wonder how many times in history has the CEO of a publicly traded company announced that his company's share price was too high and likely to fall??
Comment by
13X2413 on Mar 05, 2024 8:41pm
Maybe we should give him some credit. It turned out that he was right. Company was way overvalued.
Comment by
inthno on Mar 05, 2024 9:29pm
to lonc17 Sorry as I must have missed that when MC said that the company was over valued. Could you please point me to the pr or cc where he said that as I would like to add that to my files. Thanks in advance
Comment by
lonc17 on Mar 05, 2024 9:33pm
Apologies, I should have said, "he let everyone know" rather than "he announced"
Comment by
inthno on Mar 05, 2024 9:37pm
Yes I understand the clarification but in which cc or pr did he let everyone know that onc was over valued as I would take him to task on that as that is undermining the company.
Comment by
lonc17 on Mar 05, 2024 9:39pm
Please see my many previous posts regarding the expiration of options in December, 2023.
Comment by
lonc17 on Mar 05, 2024 10:08pm
Intho, I think you are mistaken. I do not have time tonght, but I will try to give a full rebuttal tomorrow.
Comment by
lonc17 on Mar 05, 2024 11:22pm
Intho, That's actually encouraging, as it is the only explanation as to how MC can be excused from having to report that status of the options without beihg in very serious non-compliance with sercuriies law. But is it really possible that ONC has been in a blackout period for three full months?
Comment by
JohnnyYeg on Mar 06, 2024 11:20am
Manage the Phase 3 - not finance and conduct it themselves. PanCAN had full control of the Precision Promise trial and ONCY would have been Oliver Twist to them.
Comment by
Buckhenry on Mar 06, 2024 3:10pm
Ole unnoteable filling the site with useless garbage... guess it boosts his ego..
Comment by
CMHarring218431 on Mar 06, 2024 3:45pm
Hey Buck I found the last few, especially the highlighted comments, to be very on target, noteable and reaffirming. How do you not see the relevance of so many trends which are focusing on what Pela offers? I know.... you do realize but just keep focusing on the negative. It apparently suits you!
Comment by
Buckhenry on Mar 06, 2024 4:54pm
Ok... so 2 posts out of 1000 is pertinent here.... about the the same odds as this stock ever going up significantly...